Securities fraud
Search documents
Firefly Aerospace Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - FLY
Prnewswire· 2025-11-21 13:45
Accessibility StatementSkip Navigation NEW YORK, Nov. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Firefly Aerospace Inc. ("Firefly Aerospace Inc." or the "Company") (NASDAQ: FLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Firefly Aerospace Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities other than defendants that purchased ...
FCX INVESTOR ALERT: Freeport McMoRan Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
Globenewswire· 2025-11-21 12:35
Core Viewpoint - The Freeport-McMoRan Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims related to safety issues at its Grasberg mine in Indonesia and subsequent operational impacts [1][3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Reed v. Freeport-McMoRan Inc. and covers purchasers of Freeport-McMoRan securities from February 15, 2022, to September 24, 2025 [1]. - The lawsuit alleges that Freeport-McMoRan failed to ensure adequate safety at the Grasberg Block Cave mine, leading to heightened risks for workers [3]. - On September 9, 2025, Freeport-McMoRan reported a significant incident at the Grasberg mine, resulting in a nearly 6% drop in stock price [4]. - Following a tragic incident on September 24, 2025, where two team members were fatally injured, the company disclosed that production could be approximately 35% lower than pre-incident estimates for 2026, causing a nearly 17% decline in stock price [5]. Group 2: Regulatory and Reputational Risks - The lawsuit highlights that the lack of safety measures at the Grasberg mine constituted undisclosed regulatory, litigation, and reputational risks [3]. - An article published by Bloomberg on September 25, 2025, indicated that the halt in production at the Grasberg mine could strain relations with the Indonesian government, further impacting the company's stock, which fell more than 6% following the news [6]. Group 3: Legal Process and Representation - Investors who purchased Freeport-McMoRan securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to represent the interests of the class [7]. - Robbins Geller Rudman & Dowd LLP, a leading law firm in securities fraud litigation, is representing the investors in this case [8].
JHX SHAREHOLDERS: James Hardie Industries plc CFO Steps Down – Investors with Losses Reminded of Pending Lawsuit and to Contact BFA Law by December 23
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Stock Performance - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Executive Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].
BYND SHAREHOLDERS: A Securities Investigation into Beyond Meat, Inc. has been Initiated on behalf of Investors -- Contact BFA Law if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance and Stock Movement - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material. This announcement led to a significant stock price drop of approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [4]. - Following this, on November 3, 2025, the company delayed its earnings announcement for Q3 2025 due to the need for additional time to complete the impairment review, resulting in further declines in the stock price during trading on that day [5]. Company Operations and Asset Management - In late 2023, Beyond Meat conducted a global operations review and depreciated certain long-lived assets, stating that these assets were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [2].
FCX SHAREHOLDERS: A Securities Class Action against Freeport-McMoRan Inc. has been Filed on behalf of Investors -- Contact BFA Law by January 12 if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against Freeport-McMoRan Inc. and certain senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - Freeport-McMoRan Inc. is a mining company with its Indonesian affiliate operating as PT Freeport Indonesia, which manages the Grasberg Copper and Gold Mine [4]. Incident Details - On September 9, 2025, Freeport announced the suspension of mining operations at Grasberg due to a landslide, leading to a stock price drop of $2.77 per share, or over 5.9%, from $46.66 to $43.89 [6]. - Following an update on September 24, 2025, revealing two fatalities and five missing team members, the stock price fell by $7.69 per share, or nearly 17%, from $45.36 to $37.67 [7]. - On September 25, 2025, reports indicated that the incident strained Freeport's relationship with the Indonesian government, causing the stock to drop by $2.33 per share, or over 6%, from $37.67 to $35.34 [8]. - An Indonesian news report on September 28, 2025, suggested that the landslide was preventable, indicating that the risks associated with certain mining methods were known [9]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the District of Arizona, under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3].
MLTX SHAREHOLDERS: A Securities Class Action against MoonLake Immunotherapeutics has been Filed on behalf of Investors -- Contact BFA Law by December 15
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [3]. - The company conducted Phase 3 VELA trials for sonelokimab, aimed at treating moderate to severe hidradenitis suppurativa [3]. Group 3: Clinical Data and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated higher clinical responses and differentiation of sonelokimab from competitors [4]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted by $55.75, nearly 90%, from $61.99 to $6.24 per share [6].
INSP SHAREHOLDERS: A Securities Class Action against Inspire Medical Systems, Inc. has been Filed on behalf of Investors -- Contact BFA Law by January 5 if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to delays in adoption [5][6]. - The company faced weak demand for Inspire V as many customers had excess inventory of older devices [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price plummeted by $42.04 per share, or more than 32%, from $129.95 to $87.91 between August 4 and August 5, 2025 [8].
KMX SHAREHOLDERS: A Securities Class Action against CarMax, Inc. has been Filed on behalf of Investors -- Contact BFA Law by January 2 if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6].
SNPS SHAREHOLDERS: A Securities Class Action against Synopsys, Inc. has been Filed on behalf of Investors -- Contact BFA Law by December 30 if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Synopsys, Inc. provides design automation software products used for designing and testing integrated circuits. Its Design IP segment, which supplies pre-designed silicon components to semiconductor companies, has been the fastest-growing segment, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. Financial Performance - In Q3 2025, Synopsys reported a revenue of $425.9 million for its Design IP segment, reflecting a 7.7% decline year-over-year. The net income was $242.5 million, marking a 43% year-over-year decline [6]. Allegations and Impact - The lawsuit alleges that Synopsys misled investors by stating that customers relied on its IP to minimize integration risk and speed time to market, while in reality, customers required more customization, negatively impacting the economics of the Design IP business [5]. - Following the release of disappointing financial results on September 9, 2025, Synopsys's stock price fell from $604.37 to $387.78 per share, a decline of nearly 36% [6].
LRN SHAREHOLDERS: A Securities Class Action against Stride, Inc. has been Filed on behalf of Investors -- Contact BFA Law by January 12 if You Suffered Losses
Globenewswire· 2025-11-21 11:08
Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][2]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [3]. Allegations - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students," failed to comply with employee background checks and licensure laws, and experienced poor customer service leading to higher withdrawal rates and lower conversion rates [3][4]. Stock Performance - On September 15, 2025, Stride's stock dropped by $18.60, or over 11%, from $158.36 to $139.76 per share following the fraud allegations [4]. - On October 29, 2025, after Stride admitted to poor customer experience affecting enrollments, the stock plummeted by $83.48, or more than 54%, from $153.53 to $70.05 per share [5]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [2].